WednesdaySep 20, 2017 3:25 pm

Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) is “One to Watch”

Amid a continued boom in the growing cannabis sector, Canada is moving rapidly toward legalization as the U.S. continues to foot drag at the federal level, leading many sector analysts to conclude that it’s the Canadian companies who might benefit the most as an underlying shift toward medical and recreational use continues. Out of a tiny handful of just 58 Health Canada-licensed producers, vertically integrated Emblem Corp. (TSX.V: EMC) (OTC: EMMBF) stands out as a one of the fastest growing cultivators and pharma developers, having also obtained authorization to produce cannabis oils. While sales of dried marijuana intended for smoking…

Continue Reading

WednesdaySep 20, 2017 10:07 am

The Green Organic Dutchman Rides on Quality Medical Cannabis, Private Placement and Strong Leadership

The Green Organic Dutchman (“TGOD”), a 100-percent owned subsidiary of The Green Organic Dutchman Holdings Ltd., produces high-quality medical marijuana. Its organic medical cannabis is farm grown and pesticide-free. There are many factors in favor of the company. The demand in a legal national market, consumer preference for organic foods and products of all kinds and a recent $20 million private placement are all positive signs. Also, TGOD is among a select group of companies licensed to cultivate medical cannabis by Health Canada under the Access to Cannabis for Medical Purposes Regulations. Those interested in investing should contact TGOD directly…

Continue Reading

TuesdaySep 19, 2017 4:10 pm

The Green Organic Dutchman Holdings Ltd. Announces $20M Private Placement as Company Moves toward Expansion

Company has, to date, raised $41.5 million and has more than 2,400 shareholders Has one of the largest licensed land parcels in Canada, situated on 100 acres Offers organically grown, pesticide-free medical marijuana under Canada’s ACMPR The Green Organic Dutchman Holdings Ltd. (“TGOD”), a Canadian company engaged in producing farm-grown, high-quality organic medical cannabis using craft growing, all natural, organic principles, announced on September 11 (http://cnw.fm/jHbs0) that it has entered into an agreement with a syndicate led by PI Financial Corp. to complete a private placement offering of units. The syndicate will offer, on a commercially reasonable effort basis, 4,242,500…

Continue Reading

TuesdaySep 19, 2017 3:33 pm

At ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), Medicinal Cannabinoid Quality and Safety are Founding Principles

Producer of consistent, standardized medicinal cannabis Menu of cannabis strains with varying CBD:THC ratios ABcann’s CBD-Med is one of Canada's highest-CBD products In an interview with Cantech Letter (http://cnw.fm/g2AtB), Aaron Keay, CEO of ABcann Global (TSX.V: ABCN) (OTCQB: ABCCF), talked about the factors that triggered the genesis of the company, one of Canada’s trailblazing producers of medicinal cannabis. Ken Clement, the founder of ABcann, with his wealth of experience and knowledge, had observed the variability in consistency and potency of cannabis that was currently available. Although, in general, not much of a bother to recreational users, to those using cannabis…

Continue Reading

ThursdaySep 14, 2017 2:31 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology

Proprietary biosynthesis process to produce cannabinoids Provisional patent application filed Cost-effective methodology to produce trace cannabinoids If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind. Known worldwide for his investing prowess, Warren Buffett has said, “I don't want a business that's easy for competitors. I want a business with a moat around it with a very valuable castle in the middle” (http://cnw.fm/ehB50). Naturally, the Sage of Omaha was…

Continue Reading

WednesdaySep 13, 2017 3:58 pm

Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Oral CBD Product to Be Tested by the University of British Columbia

The University of British Columbia (UBC) will conduct a double-blind study of Lexaria’s TurboCBD™ oral ingestion product TurboCBD™ masks foul tastes, protects pharmaceutical ingredients during stomach passage and increases intestinal absorption by 5-10x The UBC study will include 24 volunteers and test their cognitive and cardiovascular function after single doses and after seven days of administration Traditionally, cannabidiol (CBD) is ingested via inhalation, which can harm the lungs, and many edible products contain unwanted sugars or sweeteners. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral intake with its TurboCBD™ product. Engineered to increase absorption through the intestinal tract,…

Continue Reading

ThursdaySep 07, 2017 2:14 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues Showcasing Proprietary Research at Cannabis Investment Conferences

Proprietary Lexaria technology improves delivery of bioactive compounds in a variety of products, including cannabis-based gourmet foods Market predictions for the legal marijuana industry forecast $50 billion in sales by 2026 19 patent applications filed and pending in more than 40 countries Following a successful showing at the inaugural Institutional Capital & Cannabis Conference (IC3) in California earlier this month, Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) CEO Chris Bunka expects the company to be noticed by investors. Bunka’s presentation of the company’s latest technology slated to benefit the cannabis industry includes the world’s first clinical study on human volunteers of…

Continue Reading

ThursdayAug 31, 2017 3:34 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Begins Laboratory Venture with National Research Council

Collaborative venture could lead to strengthening of company’s patent portfolio, new commercial opportunities Firm receives patent in Australia, anticipates entering that market through cannabinoid licensing arrangements and product distribution partnerships LXRP names Allan Spissinger acting chief financial officer Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has begun laboratory work with the National Research Council ("NRC") (http://cnw.fm/Lp8bB). The collaboration will begin studies using LXRP’s patented technologies. The research will include the company’s technology in vitamins, NSAIDs, nicotine and cannabinoids utilizing lipophilic active agents. LXRP has patented technology involving how those agents are ingested into the human body in various edibles, such…

Continue Reading

TuesdayAug 29, 2017 3:52 pm

ABcann Global Corp. (TSX.V: ABCN) (OTCQB: ABCCF) Ensuring Quality of Medical Cannabis Products with Proprietary Growing Technology

Environmentally-controlled growing chambers generate consistent, superior quality Proprietary technologies eliminate risk, ensuring patients enjoy peace of mind Publicly-traded ABcann entered funding deal for $15 million at $2.25 per share The Canadian government’s recent announcement that Broken Coast Cannabis Ltd. is recalling several products sold last year after two banned pesticides were found in random samples illustrates the importance of ABcann Global Corp.’s (TSX.V: ABCN) (OTCQB: ABCCF) controlled, pesticide-free approach to growing medical marijuana (http://nnw.fm/VM7zD). Several other cannabis-growing Canadian companies also reaped the attention of authorities following mandatory testing. Hydropothecary and Peace Naturals both had products recalled earlier this year following…

Continue Reading

FridayAug 25, 2017 9:23 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Continues to Deliver Results with its Patented Technology

19 patent applications filed in the United States and internationally (under the Patent Cooperation Treaty), with national filings in 44 countries Collaborative research and development agreement with Canada’s National Research Council to investigate opportunities associated with bioavailability enhancement of certain compounds, including those in cannabinoids, vitamins, NSAIDs and nicotine Out-licenses its patented technology to third party partners, with several deals signed or pending When Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) researchers tackled the issue facing consumers of edible cannabinoids – poor absorption of the product’s bioactive compounds by the body’s gastrointestinal tract – an important statement led the way:…

Continue Reading

CanadianCannabisWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 512.354.7000